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genol mebutate can be used to treat (superficial) BCCs in pa-
tients with Gorlin–Goltz syndrome as an additional modality. 
Close clinical follow-up is recommended. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Gorlin syndrome, also known as the basal cell nevus 
syndrome (OMIM #109400), is a rare autosomal-domi-
nant genetic disease. The characteristic multiorgan ab-
normalities are caused by mutations of the patched recep-
tor gene ( PTCH1 ), a tumor suppressor gene, on chromo-
some arm 9q.  PTCH1 inhibits signaling by the membrane 
protein Smoothened (SMO). The loss-of-function muta-
tion of  PCHT1 results in an elevated activation of the son-
ic hedgehog pathway, which activates transcription fac-
tors such as GLI1. GLI1 induces cell cycle progression and 
cell proliferation and is associated in development of bas-
al cell carcinoma (BCC) and medulloblastoma. Up to 40% 
of the patients show a de-novo mutation with negative 
family history. The prevalence is 1: 60,000 with an equal 
frequency in women and men  [1, 2] .
 Most patients develop multiple BCCs already in ado-
lescence, which should raise the suspicion of Gorlin–
Goltz syndrome. The BCCs are usually located on the face 
and trunk, but also occur on sun-protected areas. All his-
tological subtypes from superficial to infiltrative and 
morphoeic BCC can be found. Aggressive forms such as 
the locally destroying ulcus terebrans are very rare. Other 
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 Abstract 
 Background: Gorlin syndrome, also known as the basal cell 
nevus syndrome (OMIM #109400), is a rare autosomal-dom-
inant genetic disease. The disease, which shows mutation of 
the patched receptor gene ( PTCH1 ) of the sonic hedgehog 
pathway, is characterized by developing multiple basal cell 
carcinomas (BCCs) in adolescent patients. Other clinical fea-
tures include mandibular keratocysts, palmar and plantar 
pits, skeletal abnormalities and malformations central ner-
vous system and genital tract. Gorlin–Goltz patients need 
multidisciplinary medical care and follow-up as well as ge-
netic counseling if the patients want to have children. The 
treatment of multiple BCCs includes conventional surgery, 
micrographic Mohs surgery, cryotherapy, laser ablation, 
photodynamic therapy, imiquimod 5% cream, 5-fluorouracil 
cream as well as the sonic hedgehog pathway inhibitor vis-
modegib.  Case Report: We report the case of a 30-year-old 
woman seen in our dermatological department since 2003. 
All the above-mentioned modalities had been employed for 
her numerous BCCs. The patient grew wary of the surgical 
procedures because of the countless scars. We successfully 
treated multiple BCCs with ingenol mebutate without post-
inflammatory scarring. At 8-month follow-up, the patient 
shows no recurrence of the treated lesions.  Conclusion: In-
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clinical features include mandibular keratocysts, palmar 
and plantar pits, skeletal abnormalities and malforma-
tions in the central nervous system and genital tract. Gor-
lin–Goltz patients need multidisciplinary medical care 
and follow-up as well as genetic counseling if the patients 
want to have children  [3] .
 The treatment of multiple BCCs includes conventional 
surgery, micrographic Mohs surgery, cryotherapy, laser 
ablation, curettage and electrodessication, photodynamic 
therapy, imiquimod 5% cream, 5-fluorouracil cream as 
well as the sonic hedgehog pathway inhibitor vismodegib. 
Radiotherapy is contraindicated, since further BCCs could 
be induced, where the mutation of the  PTCH1 gene causes 
an increased sensitivity to radiation  [4, 5] .
 Ingenol mebutate is approved as a topical treatment of 
actinic keratosis. It is believed that the local effect inhibits 
the growth of cancer cells and/or induces tumor cell 
death. The incidence of local skin reactions is high, and it 
has proven to be safe and efficacious. Successful off-label 
treatment of superficial BCCs with ingenol mebutate has 
previously been shown  [6] .
 Case Report 
 A 30-year-old Caucasian woman was diagnosed with Gorlin–
Goltz syndrome in 2003, when multiple BCCs were detected. The 
diagnosis was based on clinical features such as palmar pits, hyper-
telorism, increased head circumference, calcification of the falx 
cerebri, multiple ovarian cysts and fibromas and the radiologic ev-
idence of odontogenic keratocysts. Genotyping of the  PTCH1 gene 
detected a heterozygous mutation. Over 10 years, the patient was 
treated with numerous procedures such as micrographic Mohs sur-
gery, conventional surgery, photodynamic therapy and topical 
therapy with imiquimod cream. In 2014, we initiated a systemic 
therapy with vismodegib, which showed a pronounced response 
with decrease of most of the BCC. The patient developed alopecia, 
dysgeusia and pronounced long-lasting fatigue. Eventually, the pa-
tient decided to stop vismodegib therapy after 6 months on account 
of side effects impairing her quality of life. BCC recurred after 
3 months but the patient was tired of surgery and asked for an alter-
native therapy. Cryosurgery was very painful and also resulted in 
extensive scarring. We treated multiple BCCs on her back with 500 
μg/g of ingenol mebutate gel (fig. 1). Her husband applied the gel 
for 2 consecutive days. She reported a local inflammatory reaction, 
which healed after 2 weeks. Clinically, the treated BCCs showed 
complete resolution without scarring (fig. 2). The patient repeated 
the treatment on a regular basis without affecting her daily life and 
work. During the follow-up over 8 months, no recurrence of the 
treated BCC was detected. Of course, occasional surgery of more 
invasive BCCs was not completely unavoidable but the patient was 
happy to be able to treat many BCCs on her own without a great ef-
fort and side effects.
 Conclusion 
 Ingenol mebutate seems a suitable off-label option to 
treat (superficial) BCCs in patients with Gorlin syn-
drome. The treatment is easy to manage and patients ap-
preciate being able to treat autonomously.
 Fig. 1. Multiple clinically diagnosed BCC 
(arrows). 
 Fig. 2. Complete resolution of the BCC af-
ter topical treatment with ingenol mebu-
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